Sunday, April 19, 2026

 

US Measles vaccine gaps persist among ER patients



Study highlights need to expand vaccination education beyond primary care



University of California - Riverside

Alexandra Eftimie, Robert Rodriguez, Sahithi Malireddy 

image: 

Photo shows (L to R) Alexandra Eftimie, Robert Rodriguez, and Sahithi Malireddy.

view more 

Credit: UC Riverside School of Medicine.






RIVERSIDE, Calif. -- Measles remains one of the most contagious infectious diseases, spread through coughing and sneezing, with even small declines in vaccination coverage leading to outbreaks. As of 2026, California has reported its highest annual measles case count in seven years. In response to this growing concern, researchers have begun examining gaps in measles-related knowledge and vaccination coverage.

A UC Riverside-led study has found critical gaps in knowledge, vaccination status, and acceptance of the measles, mumps, and rubella (MMR) vaccine among patients visiting emergency departments across the United States.

Published in the American Journal of Emergency Medicine, the study examines how misinformation and access barriers may contribute to declining vaccination rates, raising concerns amid ongoing measles outbreaks.

“We found that a substantial portion of emergency department patients lack accurate knowledge about measles and the MMR vaccine,” said medical student Alexandra Eftimie, the paper’s co-lead author. “Many participants were either unsure of their vaccination status or reported not receiving the vaccine at all. Additionally, vaccine hesitancy, driven by misconceptions about safety and necessity, remains a persistent issue.”

Using survey data  (April–December 2024) from 2,459 adult patients across ten U.S. emergency departments, the study evaluated MMR vaccination status, knowledge, and willingness to receive the vaccine among a diverse population. 

“We identified key disparities in under-vaccination associated with factors such as race, language, insurance status, and access to primary care,” said Sahithi Malireddy, an undergraduate student in neuroscience and the paper’s co-lead author. “These disparities specifically emphasized how systemic barriers shape both access to vaccines and health literacy among diverse populations.” 

The researchers stress that their findings demonstrate how emergency departments can serve as critical “safety net” points of care for underserved populations who may not be able to access vaccines/healthcare in traditional formats. 

“This really offers healthcare systems an opportunity to leverage emergency departments not only for emergent care, but also as spaces to deliver accessible, evidence-based public health interventions and improve vaccine equity,” Malireddy said. “By leveraging emergency departments as points of intervention, healthcare systems may be able to reach individuals who would otherwise fall through the cracks of preventive care.”

The researchers were surprised by how often patients lacked access to clear, reliable information. 

“Many gaps stem from systemic barriers like limited literacy tools, language differences, insurance issues, and stigma,” Malireddy said. “They show how culture and access shape responses to symptoms, shifting focus from individual misunderstanding to structural inequities — and underscoring our responsibility to make healthcare knowledge accessible and actionable for marginalized communities.”

Senior author Dr. Robert Rodriguez, a professor of medicine in the UCR School of Medicine, outlined practical, low-burden steps emergency departments can take to boost MMR vaccination rates.

“While most emergency departments may not be able to administer MMR vaccines, they can still serve as high-impact sites for screening and education—especially for underserved populations,” he said. “They can inform patients about the importance of the MMR vaccine and direct them to accessible options, such as clinics and pharmacies, where they can receive it.”

Rodriguez, Eftimie, and Malireddy were joined in the study by researchers at UC San Francisco, UCLA, Rush University Medical Center, Wayne State University, Thomas Jefferson University Hospital, and Duke University School of Medicine.

The title of the paper is “Gaps in knowledge, receipt, and acceptance of measles, mumps, rubella vaccines in a national sample of emergency department patients.”

The University of California, Riverside is a doctoral research university, a living laboratory for groundbreaking exploration of issues critical to Inland Southern California, the state and communities around the world. Reflecting California's diverse culture, UCR's enrollment is more than 26,000 students. The campus opened a medical school in 2013 and has reached the heart of the Coachella Valley by way of the UCR Palm Desert Center. The campus has an annual impact of more than $2.7 billion on the U.S. economy. To learn more, visit www.ucr.edu.

 

Maternal RSV vaccination cuts infant hospitalization risk by over 80%, major UKHSA study finds



The largest real-world study of its kind shows that maternal vaccination against respiratory syncytial virus (RSV) reduces the risk of hospitalisation in young infants by over 80% when given at least two weeks before birth.



Beyond







(Saturday, 18 April 2026, Munich, Germany) The largest real-world study of its kind, presented today at ESCMID Global 2026, shows that maternal vaccination against respiratory syncytial virus (RSV) reduces the risk of hospitalisation in young infants by over 80% when given at least two weeks before birth.1

RSV is a common virus that can cause severe respiratory illness in infants and young children, including lower respiratory tract infections (LRTIs) such as bronchiolitis and pneumonia.2,3 It is a leading cause of infant hospitalisation worldwide, with early-life infection linked to potential longer-term effects including recurrent wheeze or asthma, repeat hospital admissions and impaired lung health.4, 5, 6

In England, a national maternal RSV vaccination programme was introduced on 1 September 2024, offering the Bivalent Prefusion F vaccine to pregnant women from 28 weeks’ gestation.

To evaluate its impact on infant hospitalisations due to RSV-associated LRTI, researchers from the UK Health Security Agency (UKHSA) conducted a retrospective cohort study using linked national datasets, including NHS maternity records, immunisation data and hospital and laboratory data. The analysis included 289,399 infants born between 2 September 2024 and 24 March 2025, representing around 90% of births in England during this period.

Across the study population, 4,594 RSV-associated hospitalisations were recorded. Although infants born to unvaccinated mothers made up 55% of the total cohort, they accounted for 87.2% of hospitalisations.

In contrast, infants whose mothers were vaccinated at least 14 days before birth had a markedly lower risk of hospitalisation, with vaccine effectiveness estimated at 81.3%, relative to the unvaccinated group.

Lead author and UKHSA epidemiologist Matt Wilson commented, “As the largest study to date examining the impact of this vaccine on infant hospitalisation, these findings provide robust evidence that vaccination offers substantial protection against severe illness in young infants. We found a clear relationship between timing and protection, with effectiveness increasing as the interval between vaccination and birth lengthens, reaching close to 85% when vaccination occurs at least four weeks before delivery.”

He continued, “While at least two weeks are typically needed for optimal protection, infants born 10 to 13 days after vaccination had around 50% fewer hospital admissions compared with those whose mothers were unvaccinated, whereas no reduction was seen when vaccination occurred less than 10 days before birth. This reinforces the importance of vaccinating as early as possible within the recommended window, while also showing that even when given later in pregnancy, some protection is still possible from around 10 days before birth, although earlier vaccination remains preferable.”

The study also investigated outcomes in preterm infants. Vaccine effectiveness was estimated at 69.4% in preterm infants, when allowing at least 14 days between vaccination and birth.  

“These findings are particularly important for preterm infants, who are among the most vulnerable to severe RSV infection,” added Wilson. “With sufficient time between vaccination and birth, we saw good levels of protection in these babies. Giving the vaccination early in the third trimester, as recommended by the World Health Organization, could protect most preterm infants.”

Looking ahead, Wilson said that further work is needed to assess the impact of the maternal RSV vaccination programme on infant hospitalisations at a population level and to better understand how protection changes later in infancy. He added that UKHSA will be looking at maternal vaccination and monoclonal antibody immunisation effectiveness in very preterm infants, for whom both are recommended.

He also emphasised the potential for wider global impact, explaining, “While survival from RSV bronchiolitis is high in high-income countries, it remains a major cause of infant mortality in low- and middle-income countries. These findings underscore the potential benefits of wider rollout of maternal RSV vaccination globally in line with the World Health Organization’s recommendations.”

ENDS

Notes to editors:

A reference to ESCMID Global must be included in all coverage and/or articles associated with this study. 

For more information or to arrange an expert interview, please contact the ESCMID Press Office at: communication@escmid.org

About the study author:

Matt Wilson is an epidemiologist working in the Immunisation and Vaccine Preventable Diseases division at the UK Health Security Agency and is a member of the NIHR Health Protection Research Unit in Vaccines and Immunisation. He has an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine.

About the European Society of Clinical Microbiology and Infectious Diseases:

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is the leading society for clinical microbiology and infectious diseases in Europe. ESCMID is proud to unite over 13,500 members as well as 45,000 affiliated members through 77 national and international affiliated societies. ESCMID’s mission is to champion medical progress in infection for a healthier tomorrow and plays an important role in emerging infectious diseases and antimicrobial resistance education and research.

Website: www.escmid.org/

References:

  1. Wilson, M., Whitaker, H., Walker, J., et al. (2026). Maternal RSV vaccination and reduced risk of hospitalisation for babies in England – 2024/45. Oral presentation. ESCMID Global 2026.
  2. Munro, A. P. S., MartinĂ³n-Torres, F., Drysdale, S.B. et al. (2023). The disease burden of respiratory syncytial virus in Infants. Current Opinion in Infectious Diseases. 36(5):379-384.
  3. European Lung Foundation (ELF). (n.d.). Acute lower respiratory infections. https://europeanlung.org/en/information-hub/lung-conditions/acute-lower-respiratory-infections/
  4. World Health Organization. (n.d.). Global Influenza Programme: Respiratory Syncytial Virus Surveillance. https://www.who.int/teams/global-influenza-programme/global-respiratory-syncytial-virus-surveillance
  5. World Health Organization. (2025). WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus. https://www.who.int/news/item/30-05-2025-who-outlines-recommendations-to-protect-infants-against-rsv-respiratory-syncytial-virus
  6. World Health Organization. (2025). Respiratory syncytial virus (RSV). https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)#:~:text=Respiratory%20syncytial%20virus%20(RSV)%20is,access%20to%20supportive%20medical%20care.

 

Total solar eclipse led to seismic quiet for cities within its path




Seismological Society of America






A seismic hush fell over U.S. and Canadian cities that were in the “path of totality” during the 8 April 2024 total solar eclipse, according to new research presented at the 2026 SSA Annual Meeting.

Johns Hopkins University seismologist and planetary scientist Benjamin Fernando was in an Ohio city when the eclipse occurred “and I noticed that all of a sudden everything went really quiet,” he recalled. “So I was curious as to whether that was going to be replicated in the seismic data.”

Seismic noise caused by human activity can come from construction and mining activity, crowded concerts or sporting events and the traffic of the daily commute—any activity we produce that causes the ground to shake.

After analyzing seismic noise levels across April 2024 from several hundred seismic stations, Fernando found a clear pattern of urban seismic quiet on the darkened day. First, noise levels peaked slightly before the start of totality began in a city. Noise levels then faded significantly as the sun was completely obscured by the moon. Finally, noise rose again to slightly higher than average levels for the month.

The pattern was only visible in cities, not rural areas, that were directly in the path of totality. The data did not record a hush in cities that were even slightly out of the path of totality, Fernando said. “For example, in New York it was 97% totality, but nothing changed.”

The findings suggest that cities in the path of totality experienced the eclipse as a cultural event that was significant enough to disrupt the rhythms of normal life and were places with enough ground-shaking daily activity to be noticeable when it faded away.

Covid-19 lockdowns in 2020 created one of the most famous cases of global seismic quiet related to human inactivity, dropping anthropogenic seismic noise by 50% between March and May of that year.

The new study could also help dispel the myth that the alignment of the sun, moon and Earth during an eclipse increases seismic activity, Fernando suggested.

“Folks for whatever reason sometimes push the narrative that eclipses cause earthquakes,” he said. “That’s definitely not the case, and this is another demonstration of that.”

 

HIV treatment reduces accelerated biological ageing by nearly four years, landmark study shows



A major study presented at ESCMID Global 2026 has found that antiretroviral therapy reduces accelerated biological ageing in people with HIV by nearly four years




Beyond

Age Acceleration Comparison at First Pre-ART and Final Post-Art Samples 

image: 

Age Acceleration Comparison at First Pre-ART and Final Post-Art Samples

view more 

Credit: ESCMID Global






(Monday, 20 April 2026, Munich, Germany) A major study presented today at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated biological ageing in people with HIV (PWH) by nearly four years, a finding that could transform how clinicians monitor HIV treatment and long-term health outcomes.1

Researchers developed a plasma proteomic ageing clock (PAC) – a tool that estimates biological age, reflecting physiological ageing rather than chronological age – using patterns across hundreds of blood proteins. The model was applied to participants in the Swiss HIV Cohort Study (SHCS).  

The PAC was trained on 941 plasma samples from PWH receiving successful ART and then evaluated in an independent cohort of 80 participants who contributed 294 longitudinal samples spanning viraemic pre-ART infection (when HIV was detectable in the blood) and suppressive post-ART phases.

During untreated HIV infection, the PAC estimated that participants’ biological age was accelerated by a median of 10 years. After a median duration of 1.55 years of ART, researchers observed a statistically significant mean reduction of 3.7 years in proteomic age (95% CI 2.7 to 4.7; p = 0.0001 – see Figure 1). Trajectory analyses showed that proteomic age continued to move closer to chronological age with longer ART exposure, suggesting ongoing biological recovery with sustained treatment.

Previous research suggests that PWH may experience accelerated biological ageing, which is linked to chronic inflammation and a higher risk of age-related conditions including coronary disease, 2,3 underscoring the clinical urgency of these findings.

“This research demonstrates the importance of early start and optimal adherence to ART,” commented lead study author Dr Barry Ryan, a postdoctoral researcher at EPFL, Switzerland. “We’re extremely fortunate to have a unique group from the SHCS who had samples collected for up to eight years before they started ART. With this group, we have measured the effect of untreated HIV infection and successful ART on telomere shortening, epigenetic ageing and now proteomic ageing. In each case we have shown that uncontrolled HIV infection is linked to faster ageing and that ART significantly slows this.”

The PAC primarily captures changes in inflammatory signalling and drug metabolomic pathways. When compared with the team’s previously published epigenetic ageing clock (EAC) in the same cohort, both clocks showed similar overall trends.4 However, the PAC was more sensitive to short-term immune changes, showing a faster increase during untreated infection and a more rapid decline once detectable HIV in the blood (viraemia) was suppressed with ART.

Importantly, the reversal of proteomic age acceleration after ART was not significantly associated with CD4+ or CD8+ T-cell count recovery, suggesting that the reversal reflects broader inflammatory and innate immune remodelling rather than T-cell reconstitution alone.

“Our findings support the current consensus for starting ART promptly after HIV diagnosis,” explained Dr Ryan. “The participants were closely monitored pre-ART, including CD4 and CD8 T-cell counts. Nonetheless, we observed accelerated proteomic ageing irrespective of T-cell homeostasis, with acceleration already occurring nearest the time of HIV diagnosis.”

The authors call for external validation of the PAC in more diverse global populations and for proteome-wide feature attribution studies to pinpoint the specific pathways driving HIV-related ageing biology.

 “While specific pathways of reversal may vary by ancestry and population, the global trend of accelerated ageing with untreated HIV and its attenuation after virological suppression is likely to generalise,” Dr Ryan added.

ENDS

Notes to editors:

A reference to ESCMID Global must be included in all coverage and/or articles associated with this study. 

For more information or to arrange an expert interview, please contact the ESCMID Press Office at: communication@escmid.org

About the study author:

Dr Ryan joined the Professor Jacques Fellay’s Lab of Human Genomics of Infection and Immunity in October 2025, after completing his PhD at the University of Edinburgh under Professor Ian Simpson in the area of Biomedical Artificial Intelligence. Dr Ryan comes from a computational background, having studied Electrical and Electronic Engineering in University College Cork (UCC), Ireland. He first began to train in Machine Learning (ML) and Artificial Intelligence (AI) during a master’s year in Trinity College Dublin, Ireland. This was where he first developed an interest in interdisciplinary biomedical applications of ML and AI. Ever since, he has enjoyed tackling problems of biological data integrations, characterising Parkinson’s Disease phenotypes, and now, identifying clinical insights for HIV disease research.

About the European Society of Clinical Microbiology and Infectious Diseases:

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is the leading society for clinical microbiology and infectious diseases in Europe. ESCMID is proud to unite over 13,500 members as well as 45,000 affiliated members through 77 national and international affiliated societies. ESCMID’s mission is to champion medical progress in infection for a healthier tomorrow and plays an important role in emerging infectious diseases and antimicrobial resistance education and research.

Website: www.escmid.org/

References:

  1. Ryan, B., Oumelloul, M.A., Rouached, S., et al. (2026). A plasma proteomic aging clock reflects reversal of accelerated aging in people with HIV under antiretroviral therapy. Oral presentation. ESCMID Global 2026.
  2. Nasi M., De Biasi S., Gibellini L., et al. (2016). Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017 Jan;187(1):44-52. doi: 10.1111/cei.12814. Epub 2016 Aug 9. PMID: 27198731; PMCID: PMC5167025.
  3. MartĂ­nez-MartĂ­n, P., Esteban-Cantos, A., Jurado, F., et al. (2025). Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled Human Immunodeficiency Virus (HIV-1) Infection, Clinical Infectious Diseases, ciaf537, https://doi.org/10.1093/cid/ciaf537.
  4. Schoepf, I.C., Esteban-Cantos, A., Thorball, C. et al. (2023). Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.  Lancet. Healthy Longevity4(5), e211–e218.

 

Improving oral care more than halves hospital-acquired pneumonia risk, major trial finds



A landmark trial presented at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.




Beyond





(Monday, 20 April 2026, Munich, Germany) A landmark trial presented today at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.1

The study, involving over 8,000 patients, is the only multi-centre randomised controlled trial (RCT) in a hospital setting to evaluate this approach and the largest RCT in this setting to date.

NV-HAP is a form of pneumonia that develops at least 48 hours after hospital admission in patients who are not receiving mechanical ventilation.2 It is a common healthcare-associated infection linked to longer hospital stays, higher healthcare costs and increased mortality.2 Despite occurring more frequently and being equally as dangerous as ventilator-associated pneumonia (VAP), it has historically received far less research attention.2, 3

To address this gap, researchers conducted the Hospital Acquired Pneumonia Prevention (HAPPEN) Study, a multi-centre, stepped-wedge cluster RCT across nine wards in three Australian hospitals over a 12-month period, concluding in August 2025. Each ward introduced the intervention every three months. In total, 8,870 patients were included in the study, of whom 4,347 were in wards during the intervention period.

In the intervention phase, patients were provided on admission with a toothbrush, toothpaste, educational materials and access to additional online resources. Healthcare staff received onsite training, access to online resources and practical support to improve the delivery of oral care. Control was usual practice.

The programme led to a substantial improvement in oral hygiene practices among hospital patients. The proportion of patients receiving oral care increased from 15.9% in the control to 61.5% in the intervention, with audits showing oral care was undertaken an average of 1.5 times per day.

Importantly, exposure to the intervention was associated with a statistically significant reduction in NV-HAP risk. Incidence fell from 1.00 to 0.41 cases per 100 admission days at-risk – representing an approximately 60% reduction.

“One of the most encouraging findings from this study was the scale of improvement we were able to achieve,” commented lead study author Professor Brett Mitchell, Avondale University, Australia. “Through earlier work, we identified several barriers in hospitals, including limited access to suitable products, low awareness of the link with pneumonia and competing clinical priorities. By addressing these through education, practical resources and conversations with patients on admission, we were able to substantially increase oral care in hospital wards.”

Explaining why improved oral hygiene can reduce pneumonia risk, Professor Mitchell said, “Typically, NV-HAP is the result of fluids from the mouth or throat entering the lungs, with hospital-associated respiratory pathogens more frequently detected in patients who are unable to clear oral secretions. These infections are thought to arise largely from a patient’s own microbiota rather than person-to-person transmission. Improving oral hygiene helps reduce these pathogens in the mouth, potentially lowering the risk of subsequent infection.”

Looking ahead, Professor Mitchell commented, “Guidelines already recognise the role of oral care in preventing NV-HAP, but the evidence supporting these recommendations has been limited. Our study now provides robust evidence from a hospital setting. The next step is to better understand how structured programmes can be effectively implemented and sustained across hospital wards.”

 

ENDS

 

Notes to editors:

A reference to ESCMID Global must be included in all coverage and/or articles associated with this study. 

For more information or to arrange an expert interview, please contact the ESCMID Press Office at: communication@escmid.org

About the study author:

Professor Mitchell is an internationally renowned clinician-researcher in the field of infection prevention and control. He has a particular interest in providing high-quality evidence to inform infection control practice, leading many clinical trials in this area. Based in Australia, he has received several prestigious awards, including an Order of Australia.

About the European Society of Clinical Microbiology and Infectious Diseases:

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is the leading society for clinical microbiology and infectious diseases in Europe. ESCMID is proud to unite over 13,500 members as well as 45,000 affiliated members through 77 national and international affiliated societies. ESCMID’s mission is to champion medical progress in infection for a healthier tomorrow and plays an important role in emerging infectious diseases and antimicrobial resistance education and research.

Website: www.escmid.org/

References:

  1. Mitchell, B., White, N., Russo, P., et al. (2026). The hospital acquired pneumonia prevention (HAPPEN) study: a multi-centre randomised controlled trial. Oral presentation. ESCMID Global 2026.
  2. Pittaway, H., Grudzinska, F., Livesey, A., et al. (2024). Management of non-ventilated hospital acquired pneumonia. Clinical Infection in Practice, 21, 100350.
  3. Mitchell, B. G., Russo, P. L., Cheng, A. C., et al. (2019). Strategies to reduce non-ventilator-associated hospital-acquired pneumonia: A systematic review. Infection, Disease & Health, 24(4), 229–239.

 

Largest US study finds teen cannabis use linked to slower cognitive development



Study of more than 11,000 teens finds cannabis use tied to slower gains in memory, focus and thinking speed as well as worse memory over time during key years of brain development




University of California - San Diego

Natasha Wade 

image: 

Natasha Wade, PhD, assistant professor in the Department of Psychiatry at UC San Diego School of Medicine and lead author of the study.

view more 

Credit: UC San Diego Health Sciences





Researchers from University of California San Diego have found that teenagers who begin using cannabis show slower gains in thinking and memory skills as they grow. The study, published on April 20, 2026 in Neuropsychopharmacology, analyzed data from more than 11,000 participants in the Adolescent Brain Cognitive Development (ABCD) Study, the largest long-term study of brain development in U.S. youth.

“Adolescence is a critical time for brain development, and what we’re seeing is that teens who start using cannabis aren’t improving at the same rate as their peers,” said Natasha Wade, PhD, assistant professor in the Department of Psychiatry at UC San Diego School of Medicine and lead author of the study. “These differences may seem small at first, but they can add up in ways that affect learning, memory and everyday functioning.”

The researchers followed 11,036 children starting at ages 9 to 10 through ages 16 and 17, tracking both their cognitive performance and substance use. To get a clearer picture of cannabis use, the team combined self-reports with biological testing — such as hair, urine and saliva samples — which can detect recent to several months of drug exposure.

Across a range of skills — including memory, attention, language and processing speed — teens who used cannabis showed restricted growth over time compared to those who did not. In some cases, these teens performed just as well as — or even slightly better than — others when they were younger. But as they got older and started using cannabis, their progress leveled off, while their peers continued to improve.

The study also looked more closely at different components of cannabis. In a smaller group of participants, teens with evidence of tetrahydrocannabinol (THC) exposure — the main intoxicating ingredient in cannabis — showed worse memory over time than those who did not use cannabis. Teens with evidence of cannabidiol (CBD) did not show the same pattern, although that group was small.

“These results point to THC as a likely driver of the changes we’re seeing,” Wade said. “It also highlights how complicated cannabis products can be, especially since some products labeled as CBD may still contain THC.”

While the differences seen in the study were relatively modest, researchers say they could still matter. During adolescence, the brain is rapidly developing, and even small changes in memory, attention or thinking speed can affect school performance and daily life.

The researchers note that the study does not prove cannabis use directly causes these changes. Other factors — such as environment or personality — may play a role. However, the team accounted for many of these influences, including family background, mental health and use of other substances, as well as for each participant’s prior cognitive performance.

The team will continue tracking participants into young adulthood to better understand the long-term effects of cannabis use, including how timing and frequency of use may shape brain development.

“Delaying cannabis use supports healthy brain development,” Wade said. “As cannabis becomes more widely available, it’s important for families and teens to understand how it may affect the developing brain.”

Link to full study: https://doi.org/10.1038/s41386-026-02395-1 

Additional co-authors on the study include: Ryan M. Sullivan, Alexander L. Wallace, Veronica Szpak, Joanna Jacobus and Susan F. Tapert from UC San Diego School of Medicine; Rachel Visontay, Louise Mewton and Hollie Byrne from the University of Sydney; Krista M. Lisdahl from University of Wisconsin-Milwaukee; Marilyn A. Huestis from Huestis & Smith Toxicology; and Priscila Dib Gonçalves from Columbia University.

The study was funded, in part, by the National Institute on Drug Abuse (DA050779, PI: Wade), (DA064409 PI: Sullivan), (DA062011 PI: Wallace), (T32 AA013525 PI: Riley/Spadoni to Szpak), (R01DA062432 MPI Lisdahl, Hillard), (2U01DA041025 MPI Lisdahl, Larson), (K01DA057389 PI: Gonçalves), and (NARSAD/Brain Behavior Research Foundation Gonçalves).

Authors have no conflicts of interest to disclose.